The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Sokolov P.L.

V.F. Voyno-Yasenetsky Scientific and Practical Center of Specialized Medical Care for Children

Chebanenko N.V.

Russian Medical Academy of Continuous Professional Education

Fedotova Yu.A.

Russian Medical Academy of Continuous Professional Education

Mednaya D.M.

Pirogov Russian National Research Medical University

Epileptic encephalopathy associated with a mutation in the KCNT1 gene

Authors:

Sokolov P.L., Chebanenko N.V., Fedotova Yu.A., Mednaya D.M.

More about the authors

Read: 846 times


To cite this article:

Sokolov PL, Chebanenko NV, Fedotova YuA, Mednaya DM. Epileptic encephalopathy associated with a mutation in the KCNT1 gene. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(10‑2):80‑87. (In Russ.)
https://doi.org/10.17116/jnevro202512510280

Recommended articles:
Deve­lopmental epileptic ence­phalopathy caused by a de novo muta­tion in the SCN8A gene. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10-2):136-141

References:

  1. World Health Organization. https://www.who.int/ru/news-room/fact-sheets/detail/epilepsy
  2. Thijs RD, Surges R, O’Brien TJ, et al. Epilepsy in adults. Lancet. 2019; 393(10172):689-701.  https://doi.org/10.1016/S0140-6736(18)32596-0
  3. McTague A, Howell KB, Cross JH, et al. The genetic landscape of the epileptic encephalopathies of infancy and childhood. Lancet Neurol. 2016; 15(3):304-316.  https://doi.org/10.1016/S1474-4422(15)00250-1
  4. Scheffer IE, Zuberi S, Mefford HC, et al. Developmental and epileptic encephalopathies. Nat Rev Dis Primers. 2024;10(1):61.  https://doi.org/10.1038/s41572-024-00546-6
  5. Cole BA, Clapcote SJ, Muench SP, et al. Targeting KNa1.1 channels in KCNT1-associated epilepsy. Trends Pharmacol Sci. 2021;42(8):700-713.  https://doi.org/10.1016/j.tips.2021.05.003
  6. KCNT1-Related Epilepsy. Gertler T, Bearden D, Bhattacharjee A, Carvill G. 2018 Sep 20. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle. 1993–2024.
  7. Lim CX, Ricos MG, Dibbens LM, et al. KCNT1 mutations in seizure disorders: the phenotypic spectrum and functional effects. J Med Genet. 2016;53(4):217-225.  https://doi.org/10.1136/jmedgenet-2015-103508
  8. Qunies AM, Spitznagel BD, Du Y, et al. Structure-Activity Relationship Studies in a Series of Xanthine Inhibitors of SLACK Potassium Channels. Molecules. 2024;29(11):2437. https://doi.org/10.3390/molecules29112437
  9. Rychkov GY, Shaukat Z, Lim CX, et al. Functional Effects of Epilepsy Associated KCNT1 Mutations Suggest Pathogenesis via Aberrant Inhibitory Neuronal Activity. Int J Mol Sci. 2022;23(23):15133. https://doi.org/10.3390/ijms232315133
  10. Barcia G, Fleming M, Deligniere A, et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet. 2012;44(11):1255-1259. https://doi.org/10.1038/ng.2441
  11. Borlot F, Abushama A, Morrison-Levy N, et al. KCNT1-related epilepsy: An international multicenter cohort of 27 pediatric cases. Epilepsia. 2020;61(4):679-692.  https://doi.org/10.1111/epi.16480
  12. Xu D, Chen S, Yang J, et al. Precision therapy with quinidine of KCNT1-related epileptic disorders: A systematic review. Br J Clin Pharmacol. 2022;88(12):5096-5112. https://doi.org/10.1111/bcp.15479
  13. Kholin AA, Zavadenko NN, Fedonyuk ID, et al. Early infantile epileptic encephalopathy type 14: three cases of epilepsy in infancy with migrating focal seizures due to KCNT1 mutations. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(7-2):74-82. (In Russ.). https://doi.org/10.17116/jnevro201911907274
  14. Göttlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20(24):6969-6978. https://doi.org/10.1093/emboj/20.24.6969
  15. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 2004;101(26):9861-9866. https://doi.org/10.1073/pnas.0308208101
  16. Rogawski MA. Diverse mechanisms of antiepileptic drugs in the development pipeline. Epilepsy Res. 2006;69(3):273-294.  https://doi.org/10.1016/j.eplepsyres.2006.02.004
  17. Wu PP, Cao BR, Tian FY, et al. Development of SV2A Ligands for Epilepsy Treatment: A Review of Levetiracetam, Brivaracetam, and Padsevonil. Neurosci Bull. 2024;40(5):594-608.  https://doi.org/10.1007/s12264-023-01138-2
  18. Chen Z, Brodie MJ, Liew D, et al. Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs: A 30-Year Longitudinal Cohort Study. JAMA Neurol. 2018;75(3):279-286.  https://doi.org/10.1001/jamaneurol.2018.0018
  19. Fonseca-Barriendos D, Frías-Soria CL, Pérez-Pérez D, et al. Drug-resistant epilepsy: Drug target hypothesis and beyond the receptors. Epilepsia Open. 2022;7 Suppl 1(Suppl 1):S23-S33.  https://doi.org/10.1002/epi4.12539
  20. Rogawski MA, Johnson MR. Intrinsic severity as a determinant of antiepileptic drug refractoriness. Epilepsy Curr. 2008;8(5):127-130.  https://doi.org/10.1111/j.1535-7511.2008.00272.x
  21. Sokolov P.L., Chebanenko N.V., Mednaya D.M. Genetic determinism of epilepsy refractoriness in patients with congenital cerebral p. Russkij zhurnal detskoj nevrologii. 2023;18(2-3):22-30. (In Russ.). https://doi.org/10.17650/2073-8803-2023-18-2-3-22-30
  22. Schmidt D, Löscher W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia. 2005;46(6):858-877.  https://doi.org/10.1111/j.1528-1167.2005.54904.x
  23. Sokolov PL, Chebanenko NV, Mednaya DM, et al. Epilepsy with PCDH19 mutation: polypharmacy as a consequence of the complexity and diversity of pathogenesis mechanisms. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(7):51-55. (In Russ.). https://doi.org/10.17116/jnevro202412407151

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.